BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Nathalie C. Gemayel, Eugenio Rizzello, Petar Atanasov, Daniel Wirth, Andras Borsi. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidenceCurrent Medical Research and Opinion 2019; 35(11): 1911 doi: 10.1080/03007995.2019.1631058
2
InfliximabReactions Weekly 2015; 1569(1): 131 doi: 10.1007/s40278-015-5475-9
3
C. Fradet, J. Kern, P. Atanasov, D. Wirth, A. Borsi. Impact of surgery and its complications in ulcerative colitis patients in clinical practice: A systematic literature review of real-world evidence in EuropeInternational Journal of Surgery Open 2020; 22: 22 doi: 10.1016/j.ijso.2019.11.010
4
Erika Lehtola, Johanna Haapamäki, Martti A. Färkkilä. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-upScandinavian Journal of Gastroenterology 2016; 51(12): 1476 doi: 10.1080/00365521.2016.1218539
5
Daniel J Wong, Eve M Roth, Joseph D Feuerstein, Vitaliy Y Poylin. Surgery in the age of biologicsGastroenterology Report 2019; 7(2): 77 doi: 10.1093/gastro/goz004
6
Yuka Marutani, Tsutomu Mizoshita, Tomoya Sugiyama, Shozo Togawa, Takahito Katano, Tomonori Yamada, Yoshikazu Hirata, Yoshihide Kimura, Tomokatsu Miyaki, Yusuke Inoue, Erina Suzuki, Makoto Sasaki, Hiromi Kataoka. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practiceIndian Journal of Gastroenterology 2020;  doi: 10.1007/s12664-020-01092-1
7
Salvatore Bellinvia, J. R. Fraser Cummings, Michael R. Ardern-Jones, Christopher J. Edwards. Adalimumab Biosimilars in Europe: An Overview of the Clinical EvidenceBioDrugs 2019; 33(3): 241 doi: 10.1007/s40259-019-00355-4
8
Antonio Tursi, Walter Elisei, Roberto Faggiani, Leonardo Allegretta, Nicola Della Valle, Giacomo Forti, Marilisa Franceschi, Antonio Ferronato, Sara Gallina, Tiziana Larussa, Francesco Luzza, Roberto Lorenzetti, Giammarco Mocci, Antonio Penna, Stefano Rodino’, Ladislava Sebkova, Antonio de Medici, Giuseppe Pranzo, Cristina Ricciardelli, Giuseppina Grasso, Stefano Scorza, Costantino Zampaletta, Marcello Picchio. Effectiveness and safety of adalimumab to treat outpatient ulcerative colitisMedicine 2018; 97(34): e11897 doi: 10.1097/MD.0000000000011897
9
Christopher M. Black, Eric Yu, Eilish McCann, Sumesh Kachroo, Laszlo Gulacsi. Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World DataPLOS ONE 2016; 11(2): e0149692 doi: 10.1371/journal.pone.0149692
10
Bernadette Pöllinger, Wolfgang Schmidt, Anna Seiffert, Heidi Imhoff, Martin Emmert. Costs of dose escalation among ulcerative colitis patients treated with adalimumab in GermanyThe European Journal of Health Economics 2019; 20(2): 195 doi: 10.1007/s10198-017-0953-z
11
Marta Maia Bosca-Watts, Xavier Cortes, Marisa Iborra, Jose Maria Huguet, Laura Sempere, Gloria Garcia, Rafa Gil, MariFe Garcia, Marga Muñoz, Pedro Almela, Nuria Maroto, Jose Maria Paredes. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter studyWorld Journal of Gastroenterology 2016; 22(47): 10432-10439 doi: 10.3748/wjg.v22.i47.10432
12
Marie Muller, Ferdinando D’Amico, Stefanos Bonovas, Silvio Danese, Laurent Peyrin-Biroulet. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic ReviewJournal of Crohn's and Colitis 2020;  doi: 10.1093/ecco-jcc/jjaa186
13
Kymberley Thorne, Laith Alrubaiy, Ashley Akbari, David G. Samuel, Sian Morrison-Rees, Stephen E. Roberts. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporinEuropean Journal of Gastroenterology & Hepatology 2016; 28(4): 369 doi: 10.1097/MEG.0000000000000568